1. Single-Cell RNA-seq Analysis Utilized to Evaluate Products such as Those Used in Cellular Medicine
By using a next generation sequencer, it is possible to rapidly evaluate the comprehensive gene expression data at the single cell level, which facilitates accurate evaluation of each cell. Furthermore, the bioinformatics analysis of a vast amount of gene expression data can reveal biomarkers that can distinguish target/non-target cells and the optimal conditions for differentiation.
Click Here for Details
Classification and visualization of the expression profile for each cell
Single cell RNA-seq analysis can detect the heterogeneity (sub-population) within samples by using the large-scale gene expression data from each cell, and estimate the cell types in each sub-populations. This analysis also makes it possible to accurately evaluate whether or not differentiation into the target cells has been achieved.
2. Analysis of Differentiation Status by Metabolomics and Proteomics of Cell Lysates or Media
Axcelead provides comprehensive analysis of both small molecules and proteins in the medium and the cells under various culture conditions at various time points, which supports the exploration of essential components or predictive markers for differentiation. In the early stages of costly and time consuming differentiation culturing, we strive to explore predictive markers that determine the possibility of successful differentiation or proliferation, to enable the stable and efficient production of the target cells.
Simultaneous analysis of sugars, lipids, amino and nucleic acids, vitamins, and other endogenous small molecules
Comprehensive analysis of more than 4,000 proteins
3. Phenotypic Screening using iPS Cells
At Axcelead, to discover the compounds with the activity clients require, we perform compound screening using iPS cells with large-scale, pharma-origin, and high-quality small molecule libraries. The utilization of our diversity compound libraries makes it possible for you to obtain hit compounds that improve the efficiency of differentiation into target tissues or suppress disease phenotypes.
Treatment of iPS-derived cardiomyocytes with a hit compound “X” decreased the expression of disease-relevant protein (data source: BNP), without cytotoxicity (data source: nuclei), suggesting that this compound shows promising activity.